COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00113308 |
Recruitment Status :
Completed
First Posted : June 8, 2005
Last Update Posted : March 14, 2017
|
Sponsor:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Arthritis, Rheumatoid | Drug: GW406381 | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2208 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis |
Study Start Date : | June 2005 |
Actual Primary Completion Date : | September 2006 |
Actual Study Completion Date : | September 2006 |
Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics:
Rheumatoid arthritis
Primary Outcome Measures :
- Percentage of American College of Rheumatology (ACR)20 Responders at Week 12 [ Time Frame: Week 12 ]
Secondary Outcome Measures :
- Change from baseline to each scheduled visit in tender/painful joint count (68 joint panel) [ Time Frame: Baseline and Week 12 ]
- Change from baseline to each scheduled visit in swollen joint count (66 joint panel) [ Time Frame: Baseline and Week 12 ]
- Change from baseline to each scheduled visit in patient's pain assessment (VAS) [ Time Frame: Baseline and Week 12 ]
- Change from baseline to each scheduled visit in physician's global assessment of arthritis condition [ Time Frame: Baseline and Week 12 ]
- Change from baseline to each scheduled visit in patient's global assessment of arthritis condition [ Time Frame: Baseline and Week 12 ]
- Change from baseline to each scheduled visit in functional disability index (HAQ) [ Time Frame: Baseline and Week 12 ]
- Change between baseline and end of treatment (or early withdrawal) in the Short Form - McGill Pain Questionnaire (SF-MPQ) [ Time Frame: Baseline and Up to Week 12 ]
- Change from baseline to each scheduled visit in C-reactive protein (CRP) [ Time Frame: Baseline and up to Week 12 ]
- Number of participants withdrawing from the study due to lack of efficacy [ Time Frame: Week 12 ]
- Number of participants who received supplementary analgesic therapy [ Time Frame: Week 12 ]
- Changes from pretreatment to on treatment and post-treatment follow-up in vital signs- systolic blood pressure (SBP) and diastolic blood pressure (DBP) [ Time Frame: Baseline and up to Week 12 ]
- Changes from pretreatment to on treatment and post-treatment follow-up in vital signs- heart rate (HR) [ Time Frame: Baseline and up to Week 12 ]
- Changes from pretreatment to on treatment and post-treatment follow-up in weight [ Time Frame: Baseline and Week 12 ]
- Number of participants with change in BMI of potential clinical concern [ Time Frame: Week 4, 4, 8, 12 and foloow up ]
- Number of participants with change from baseline of pedal oedema (including diuretic use) [ Time Frame: Baseline and up to Week 12 ]
- Change from baseline in 12-lead electrocardiograms (ECGs) [ Time Frame: Baseline and up to Week 12 ]
- Change from baseline in clinical chemistry parameters: Albumin [ Time Frame: Baseline and up to Week 12 ]
- Change from baseline in clinical chemistry parameters: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase [ Time Frame: Baseline and Up to Week 12 ]
- Change from baseline in clinical chemistry parameters: Total Bilirubin [ Time Frame: Baseline and up to Week 12 ]
- Change from baseline in clinical chemistry parameters: Carbon Dioxide content /Bicarbonate, Glucose, Potassium, Sodium [ Time Frame: Baseline and up to Week 12 ]
- Change from baseline in clinical chemistry parameters: Creatinine [ Time Frame: Baseline and up to Week 12 ]
- Change from baseline in haematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet count, White Blood Cell count [ Time Frame: Baseline and up to Week 12 ]
- Change from baseline in haematology parameters: Hemoglobin [ Time Frame: Baseline and up to Week 12 ]
- Change from baseline in haematology parameters: Mean Corpuscle volume [ Time Frame: Baseline and Up to Week 12 ]
- Change from baseline in haematology parameters: Red Blood Cell count [ Time Frame: Baseline and up to Week 12 ]
- Urinalysis assessment [ Time Frame: Up to Week 12 ]
- Number of participants with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Upto Week 12 ]
- Change in the Short Form-36 (SF-36v2) subscale scores between baseline and the end of treatment (or early withdrawal) [ Time Frame: Baseline and Week 12 ]
- Change in the Short Form-36 (SF-36v2) Physical component summary score and mental component summary score between baseline and the end of treatment (or early withdrawal) [ Time Frame: Baseline and Week 12 ]
- Psychometrically test and validate the amended Patient Satisfaction with Pain Medication questionnaire [ Time Frame: Week 12 ]
- Change between baseline and end of treatment (or early withdrawal) in the EuroQoL Questionnaire -5 Dimensions (EQ-5D) utility score, using European population utility tariff [ Time Frame: Baseline and Week 12 ]
- Change between baseline and end of treatment (or early withdrawal) in the fatigue/inertia factor of the Profile of Moods States Brief Form (POMS-B) [ Time Frame: Baseline and Week 12 ]
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Rheumatoid arthritis (RA) for at least 12 months.
- Required a non-steroidal anti-inflammatory drug (NSAID) or COX-2 inhibitor for RA for at least 5 out of 7 days of each week for the 4 weeks prior to screening.
Exclusion criteria:
- Any history of cardiovascular disease (e.g., heart attack, stroke, congestive heart failure, uncontrolled high blood pressure), documented peripheral arterial insufficiency and symptomatic, clinically significant claudication, or who have a history of peripheral arterial embolism.
- Have an active stomach ulcer or history of any stomach tear or bleeding.
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00113308
Locations


United States, Alabama | |
GSK Investigational Site | |
Anniston, Alabama, United States, 36207 | |
GSK Investigational Site | |
Birmingham, Alabama, United States, 35205 | |
GSK Investigational Site | |
Birmingham, Alabama, United States, 35215 | |
GSK Investigational Site | |
Huntsville, Alabama, United States, 35801 | |
GSK Investigational Site | |
Montgomery, Alabama, United States, 36106 | |
GSK Investigational Site | |
Montgomery, Alabama, United States, 36111 | |
United States, Arizona | |
GSK Investigational Site | |
Glendale, Arizona, United States, 85308 | |
GSK Investigational Site | |
Scottsdale, Arizona, United States, 85251 | |
GSK Investigational Site | |
Tucson, Arizona, United States, 85704 | |
GSK Investigational Site | |
Tucson, Arizona, United States, 85719 | |
United States, California | |
GSK Investigational Site | |
Anaheim, California, United States, 92801 | |
GSK Investigational Site | |
Palm Desert, California, United States, 92260 | |
GSK Investigational Site | |
San Diego, California, United States, 92103-6204 | |
GSK Investigational Site | |
San Diego, California, United States, 92108 | |
GSK Investigational Site | |
San Diego, California, United States, 92128 | |
GSK Investigational Site | |
Santa Monica, California, United States, 90048 | |
GSK Investigational Site | |
Upland, California, United States, 91786 | |
United States, Colorado | |
GSK Investigational Site | |
Colorado Springs, Colorado, United States, 80909 | |
United States, Connecticut | |
GSK Investigational Site | |
Bridgeport, Connecticut, United States, 06606 | |
GSK Investigational Site | |
Danbury, Connecticut, United States, 06810 | |
GSK Investigational Site | |
Hamden, Connecticut, United States, 06518 | |
GSK Investigational Site | |
Trumbull, Connecticut, United States, 06611 | |
United States, Florida | |
GSK Investigational Site | |
Aventura, Florida, United States, 33180 | |
GSK Investigational Site | |
Daytona Beach, Florida, United States, 32114 | |
GSK Investigational Site | |
Deland, Florida, United States, 32720 | |
GSK Investigational Site | |
Dunedin, Florida, United States, 34698 | |
GSK Investigational Site | |
Largo, Florida, United States, 33773 | |
GSK Investigational Site | |
Miami, Florida, United States, 33156 | |
GSK Investigational Site | |
Miami, Florida, United States, 33173 | |
GSK Investigational Site | |
Ocala, Florida, United States, 34474 | |
GSK Investigational Site | |
Orlando, Florida, United States, 32804 | |
GSK Investigational Site | |
Orlando, Florida, United States, 32806 | |
GSK Investigational Site | |
Palm Harbor, Florida, United States, 34684 | |
GSK Investigational Site | |
Port Orange, Florida, United States, 32127 | |
GSK Investigational Site | |
Stuart, Florida, United States, 34996 | |
GSK Investigational Site | |
Tampa, Florida, United States, 33614 | |
GSK Investigational Site | |
Trinity, Florida, United States, 34655 | |
GSK Investigational Site | |
West Palm Beach, Florida, United States, 33409 | |
GSK Investigational Site | |
Zephyrhills, Florida, United States, 33540 | |
United States, Georgia | |
GSK Investigational Site | |
Atlanta, Georgia, United States, 30342 | |
GSK Investigational Site | |
Gainsville, Georgia, United States, 30501 | |
GSK Investigational Site | |
Roswell, Georgia, United States, 30075 | |
GSK Investigational Site | |
Woodstock, Georgia, United States, 30189 | |
United States, Idaho | |
GSK Investigational Site | |
Idaho Falls, Idaho, United States, 83401 | |
United States, Illinois | |
GSK Investigational Site | |
Evanston, Illinois, United States, 60201 | |
GSK Investigational Site | |
Morton Grove, Illinois, United States, 60053 | |
GSK Investigational Site | |
Springfield, Illinois, United States, 62704 | |
United States, Indiana | |
GSK Investigational Site | |
Evansville, Indiana, United States, 47714 | |
GSK Investigational Site | |
Indianapolis, Indiana, United States, 46202 | |
GSK Investigational Site | |
Indianapolis, Indiana, United States, 46227 | |
United States, Kansas | |
GSK Investigational Site | |
Prairie Village, Kansas, United States, 66206 | |
GSK Investigational Site | |
Wichita, Kansas, United States, 67207 | |
United States, Kentucky | |
GSK Investigational Site | |
Louisville, Kentucky, United States, 40202 | |
GSK Investigational Site | |
Louisville, Kentucky, United States, 40207 | |
GSK Investigational Site | |
Louisville, Kentucky, United States, 40213 | |
United States, Louisiana | |
GSK Investigational Site | |
New Orleans, Louisiana, United States, 70115 | |
GSK Investigational Site | |
Slidell, Louisiana, United States, 70458 | |
United States, Maryland | |
GSK Investigational Site | |
Wheaton, Maryland, United States, 20902 | |
United States, Massachusetts | |
GSK Investigational Site | |
Fall River, Massachusetts, United States, 02720 | |
GSK Investigational Site | |
Springfield, Massachusetts, United States, 01107 | |
United States, Michigan | |
GSK Investigational Site | |
Kalamazoo, Michigan, United States, 49048 | |
GSK Investigational Site | |
Lansing, Michigan, United States, 48910 | |
United States, Missouri | |
GSK Investigational Site | |
St. Louis, Missouri, United States, 63117 | |
GSK Investigational Site | |
St. Louis, Missouri, United States, 63141 | |
United States, Nevada | |
GSK Investigational Site | |
Las Vegas, Nevada, United States, 89103 | |
GSK Investigational Site | |
Las Vegas, Nevada, United States, 89106 | |
GSK Investigational Site | |
Las Vegas, Nevada, United States, 89128 | |
GSK Investigational Site | |
Reno, Nevada, United States, 89502 | |
United States, New Hampshire | |
GSK Investigational Site | |
Dover, New Hampshire, United States, 03820 | |
United States, New Jersey | |
GSK Investigational Site | |
Berlin, New Jersey, United States, 08009 | |
GSK Investigational Site | |
Mercerville, New Jersey, United States, 08619 | |
United States, New York | |
GSK Investigational Site | |
Johnson City, New York, United States, 13790 | |
GSK Investigational Site | |
Kingston, New York, United States, 12401 | |
GSK Investigational Site | |
New York, New York, United States, 10024 | |
GSK Investigational Site | |
North Massapequa, New York, United States, 11758 | |
GSK Investigational Site | |
Rochester, New York, United States, 14618 | |
United States, North Carolina | |
GSK Investigational Site | |
Charlotte, North Carolina, United States, 28210 | |
GSK Investigational Site | |
Gastonia, North Carolina, United States, 28054 | |
GSK Investigational Site | |
Hickory, North Carolina, United States, 28601 | |
GSK Investigational Site | |
Statesville, North Carolina, United States, 28625 | |
United States, Ohio | |
GSK Investigational Site | |
Cleveland, Ohio, United States, 44130 | |
GSK Investigational Site | |
Columbus, Ohio, United States, 43210 | |
GSK Investigational Site | |
Concinnati, Ohio, United States, 45219 | |
GSK Investigational Site | |
Mayfield Village, Ohio, United States, 44143 | |
United States, Oklahoma | |
GSK Investigational Site | |
Oklahoma City, Oklahoma, United States, 73112 | |
GSK Investigational Site | |
Tulsa, Oklahoma, United States, 74104 | |
GSK Investigational Site | |
Tulsa, Oklahoma, United States, 74135 | |
United States, Oregon | |
GSK Investigational Site | |
Medford, Oregon, United States, 97504 | |
United States, Pennsylvania | |
GSK Investigational Site | |
Duncansville, Pennsylvania, United States, 16635 | |
GSK Investigational Site | |
Philadelphia, Pennsylvania, United States, 19118 | |
GSK Investigational Site | |
Philadelphia, Pennsylvania, United States, 19140 | |
GSK Investigational Site | |
West Reading, Pennsylvania, United States, 19611 | |
United States, South Carolina | |
GSK Investigational Site | |
Charleston, South Carolina, United States, 29406 | |
GSK Investigational Site | |
Charleston, South Carolina, United States, 29407 | |
GSK Investigational Site | |
Greer, South Carolina, United States, 29651 | |
GSK Investigational Site | |
Hampton, South Carolina, United States, 29924 | |
GSK Investigational Site | |
Murrells Inlet, South Carolina, United States, 29576 | |
United States, Tennessee | |
GSK Investigational Site | |
Memphis, Tennessee, United States, 38119 | |
United States, Texas | |
GSK Investigational Site | |
Austin, Texas, United States, 78705 | |
GSK Investigational Site | |
Dallas, Texas, United States, 75231 | |
GSK Investigational Site | |
San Antonio, Texas, United States, 78229 | |
GSK Investigational Site | |
San Antonio, Texas, United States, 78232 | |
United States, Washington | |
GSK Investigational Site | |
Everett, Washington, United States, 98201 | |
GSK Investigational Site | |
Vancouver, Washington, United States, 98664 | |
United States, Wisconsin | |
GSK Investigational Site | |
Racine, Wisconsin, United States, 53404 | |
Argentina | |
GSK Investigational Site | |
Cordoba, Córdova, Argentina | |
GSK Investigational Site | |
Córdoba, Córdova, Argentina, 5000 | |
GSK Investigational Site | |
Rosario, Santa Fe, Argentina, 2000 | |
GSK Investigational Site | |
Ciudad Autónoma de Buenos Aires, Argentina, 1013 | |
GSK Investigational Site | |
Ciudad Autónoma de Buenos Aires, Argentina, 1427 | |
GSK Investigational Site | |
Ciudad Autónoma de Buenos Aires, Argentina, C1121ABE | |
GSK Investigational Site | |
Ciudad Autónoma de Buenos Aires, Argentina, C1128AAF | |
GSK Investigational Site | |
Ciudad Autónoma de Buenos Aires, Argentina, C1426BOR | |
GSK Investigational Site | |
Cordoba, Argentina, 5000 | |
GSK Investigational Site | |
Quilmes, Argentina, 1878 | |
GSK Investigational Site | |
San Juan, Argentina, 5400 | |
GSK Investigational Site | |
Tucuman, Argentina, 4000 | |
Austria | |
GSK Investigational Site | |
Vienna, Austria, A-1021 | |
GSK Investigational Site | |
Vienna, Austria, A-1060 | |
GSK Investigational Site | |
Vienna, Austria, A-1090 | |
GSK Investigational Site | |
Vienna, Austria, A-1100 | |
Belgium | |
GSK Investigational Site | |
Antwerpen, Belgium, 2020 | |
GSK Investigational Site | |
Diepenbeek, Belgium, 3590 | |
GSK Investigational Site | |
Lommel, Belgium, 3920 | |
GSK Investigational Site | |
Mons, Belgium, 7000 | |
Bulgaria | |
GSK Investigational Site | |
Pleven, Bulgaria, 5800 | |
GSK Investigational Site | |
Sofia, Bulgaria, 1233 | |
GSK Investigational Site | |
Sofia, Bulgaria, 1431/1000 | |
GSK Investigational Site | |
Sofia, Bulgaria, 1431 | |
GSK Investigational Site | |
Varna, Bulgaria, 9010 | |
Canada, Alberta | |
GSK Investigational Site | |
Edmonton, Alberta, Canada, T5K 2A2 | |
Canada, British Columbia | |
GSK Investigational Site | |
Penticton, British Columbia, Canada, V2A 3G8 | |
GSK Investigational Site | |
Victoria, British Columbia, Canada, V8P 5P6 | |
Canada, Manitoba | |
GSK Investigational Site | |
Winnipeg, Manitoba, Canada, R3A 1M3 | |
Canada, Newfoundland and Labrador | |
GSK Investigational Site | |
Saint John's, Newfoundland and Labrador, Canada, A1B 3E1 | |
Canada, Ontario | |
GSK Investigational Site | |
Kitchener, Ontario, Canada, N2M 5N6 | |
GSK Investigational Site | |
Mississauga, Ontario, Canada, L5M 2V8 | |
GSK Investigational Site | |
Toronto, Ontario, Canada, M4N 3M5 | |
GSK Investigational Site | |
Toronto, Ontario, Canada, M5T 2S8 | |
GSK Investigational Site | |
Toronto, Ontario, Canada, M9W 4L6 | |
GSK Investigational Site | |
Windsor, Ontario, Canada, N8X 5A6 | |
Canada, Quebec | |
GSK Investigational Site | |
Montreal, Quebec, Canada, H3T 1E2 | |
GSK Investigational Site | |
Montreal, Quebec, Canada, H3Z 2Z3 | |
GSK Investigational Site | |
Sainte-Foy, Quebec, Canada, G1W 4R4 | |
GSK Investigational Site | |
St-Jerome, Quebec, Canada, J7Z 5T3 | |
GSK Investigational Site | |
Trois-Rivieres, Quebec, Canada, G8Z 1Y2 | |
Canada, Saskatchewan | |
GSK Investigational Site | |
Saskatoon, Saskatchewan, Canada, S7N 0W8 | |
Chile | |
GSK Investigational Site | |
Santiago, Región Metro De Santiago, Chile, 8380456 | |
GSK Investigational Site | |
Santiago, Región Metro De Santiago, Chile | |
GSK Investigational Site | |
Viña del Mar, Valparaíso, Chile | |
Costa Rica | |
GSK Investigational Site | |
San Jose, Costa Rica | |
Denmark | |
GSK Investigational Site | |
Aalborg, Denmark, 9000 | |
GSK Investigational Site | |
Ishoj, Denmark, 2635 | |
GSK Investigational Site | |
Odense C, Denmark, 5000 | |
GSK Investigational Site | |
Vejle, Denmark, 7100 | |
Finland | |
GSK Investigational Site | |
Helsinki, Finland, 00100 | |
GSK Investigational Site | |
Hyvinkaa, Finland, 05800 | |
GSK Investigational Site | |
Kuopio, Finland, 70100 | |
France | |
GSK Investigational Site | |
Angers, France, 49100 | |
GSK Investigational Site | |
Cahors cedex 9, France, 46005 | |
GSK Investigational Site | |
Chilly Mazarin, France, 91380 | |
GSK Investigational Site | |
Corbeil Essonnes Cedex, France, 91106 | |
GSK Investigational Site | |
Grenoble cedex 09, France, 38042 | |
GSK Investigational Site | |
Lyon, France, 69002 | |
GSK Investigational Site | |
Paris cedex 12, France, 75571 | |
GSK Investigational Site | |
Toulouse, France, 31300 | |
GSK Investigational Site | |
Tours, France, 37000 | |
Germany | |
GSK Investigational Site | |
Baden-Baden, Baden-Wuerttemberg, Germany, 76530 | |
GSK Investigational Site | |
Deggingen, Baden-Wuerttemberg, Germany, 73326 | |
GSK Investigational Site | |
Freiburg, Baden-Wuerttemberg, Germany, 79098 | |
GSK Investigational Site | |
Kippenheim, Baden-Wuerttemberg, Germany, 77971 | |
GSK Investigational Site | |
Stuttgart, Baden-Wuerttemberg, Germany, 66111 | |
GSK Investigational Site | |
Stuttgart, Baden-Wuerttemberg, Germany, 70469 | |
GSK Investigational Site | |
Weinheim, Baden-Wuerttemberg, Germany, 69469 | |
GSK Investigational Site | |
Bayreuth, Bayern, Germany, 95445 | |
GSK Investigational Site | |
Erlangen, Bayern, Germany, 91054 | |
GSK Investigational Site | |
Muenchen, Bayern, Germany, 80333 | |
GSK Investigational Site | |
Muenchen, Bayern, Germany, 80339 | |
GSK Investigational Site | |
Nuernberg, Bayern, Germany, 90402 | |
GSK Investigational Site | |
Passau, Bayern, Germany, 94032 | |
GSK Investigational Site | |
Huettenberg, Hessen, Germany, 35625 | |
GSK Investigational Site | |
Wiesbaden, Hessen, Germany, 65185 | |
GSK Investigational Site | |
Schwerin, Mecklenburg-Vorpommern, Germany, 19055 | |
GSK Investigational Site | |
Einbeck, Niedersachsen, Germany, 37574 | |
GSK Investigational Site | |
Hannover, Niedersachsen, Germany, 30519 | |
GSK Investigational Site | |
Hildesheim, Niedersachsen, Germany, 31134 | |
GSK Investigational Site | |
Aachen, Nordrhein-Westfalen, Germany, 52064 | |
GSK Investigational Site | |
Beckum, Nordrhein-Westfalen, Germany, 59269 | |
GSK Investigational Site | |
Bochum, Nordrhein-Westfalen, Germany, 44787 | |
GSK Investigational Site | |
Essen, Nordrhein-Westfalen, Germany, 45326 | |
GSK Investigational Site | |
Goch, Nordrhein-Westfalen, Germany, 47574 | |
GSK Investigational Site | |
Hattingen, Nordrhein-Westfalen, Germany, 45525 | |
GSK Investigational Site | |
Koeln, Nordrhein-Westfalen, Germany, 51069 | |
GSK Investigational Site | |
Muenster, Nordrhein-Westfalen, Germany, 48155 | |
GSK Investigational Site | |
Witten, Nordrhein-Westfalen, Germany, 58455 | |
GSK Investigational Site | |
Rhaunen, Rheinland-Pfalz, Germany, 55624 | |
GSK Investigational Site | |
Saarbruecken, Saarland, Germany, 66111 | |
GSK Investigational Site | |
Wolmirstedt, Sachsen-Anhalt, Germany, 39326 | |
GSK Investigational Site | |
Chemnitz, Sachsen, Germany, 09111 | |
GSK Investigational Site | |
Delitzsch, Sachsen, Germany, 04509 | |
GSK Investigational Site | |
Dresden, Sachsen, Germany, 01067 | |
GSK Investigational Site | |
Freital, Sachsen, Germany, 01705 | |
GSK Investigational Site | |
Goerlitz, Sachsen, Germany, 02826 | |
GSK Investigational Site | |
Leipzig, Sachsen, Germany, 04107 | |
GSK Investigational Site | |
Leipzig, Sachsen, Germany, 04229 | |
GSK Investigational Site | |
Schmiedeberg, Sachsen, Germany, 01762 | |
GSK Investigational Site | |
Elmshorn, Schleswig-Holstein, Germany, 25335 | |
GSK Investigational Site | |
Luebeck, Schleswig-Holstein, Germany, 23538 | |
GSK Investigational Site | |
Pinneberg, Schleswig-Holstein, Germany, 25421 | |
GSK Investigational Site | |
Berlin, Germany, 10777 | |
GSK Investigational Site | |
Berlin, Germany, 12247 | |
GSK Investigational Site | |
Berlin, Germany, 13125 | |
GSK Investigational Site | |
Berlin, Germany, 14057 | |
GSK Investigational Site | |
Berlin, Germany, 14109 | |
GSK Investigational Site | |
Hamburg, Germany, 20249 | |
GSK Investigational Site | |
Hamburg, Germany, 22143 | |
GSK Investigational Site | |
Hamburg, Germany, 22415 | |
Greece | |
GSK Investigational Site | |
Kavala, Greece, 65403 | |
GSK Investigational Site | |
Thessaloniki, Greece, 546 36 | |
GSK Investigational Site | |
Thessaloniki, Greece, 54642 | |
GSK Investigational Site | |
Thessaloniki, Greece, 564 29 | |
Hungary | |
GSK Investigational Site | |
Budapest, Hungary, 1023 | |
GSK Investigational Site | |
Budapest, Hungary, 1238 | |
GSK Investigational Site | |
Budapest, Hungary | |
GSK Investigational Site | |
Győr, Hungary, 9024 | |
India | |
GSK Investigational Site | |
Bangalore, India, 560 017 | |
GSK Investigational Site | |
Bangalore, India, 560 054 | |
GSK Investigational Site | |
Bangalore, India, 560034 | |
GSK Investigational Site | |
Chennai, India, 600003 | |
GSK Investigational Site | |
Hyderabad, Andhra Pradesh, India, 500482 | |
GSK Investigational Site | |
Hyderabad, India, 500 004 | |
GSK Investigational Site | |
New Delhi, India | |
GSK Investigational Site | |
Pune., India, 411 001 | |
Ireland | |
GSK Investigational Site | |
Dublin, Ireland, 9 | |
GSK Investigational Site | |
Waterford, Ireland | |
Italy | |
GSK Investigational Site | |
Pescara, Abruzzo, Italy, 65100 | |
GSK Investigational Site | |
Benevento, Campania, Italy, 82100 | |
GSK Investigational Site | |
Telese Terme (BN), Campania, Italy, 82100 | |
GSK Investigational Site | |
Arenzano (GE), Liguria, Italy, 16011 | |
GSK Investigational Site | |
Genova, Liguria, Italy, 16148 | |
GSK Investigational Site | |
Rozzano (MI), Lombardia, Italy, 20089 | |
GSK Investigational Site | |
Pisa, Toscana, Italy, 56126 | |
GSK Investigational Site | |
Prato, Toscana, Italy, 59100 | |
GSK Investigational Site | |
Terni, Umbria, Italy, 05100 | |
GSK Investigational Site | |
Montebelluna (TV), Veneto, Italy, 31044 | |
Korea, Republic of | |
GSK Investigational Site | |
Anyang-Si, Korea, Republic of, 431-070 | |
GSK Investigational Site | |
Daegu, Korea, Republic of, 705-718 | |
GSK Investigational Site | |
Seoul, Korea, Republic of, 110-744 | |
GSK Investigational Site | |
Seoul, Korea, Republic of, 120-752 | |
GSK Investigational Site | |
Seoul, Korea, Republic of, 138-736 | |
GSK Investigational Site | |
Seoul, Korea, Republic of | |
Latvia | |
GSK Investigational Site | |
Liepaja, Latvia, LV3400 | |
GSK Investigational Site | |
Riga, Latvia, LV 1002 | |
GSK Investigational Site | |
Riga, Latvia, LV1079 | |
GSK Investigational Site | |
Valmiera, Latvia | |
Mexico | |
GSK Investigational Site | |
Guadalajara, Jalisco, Mexico, 44280 | |
GSK Investigational Site | |
Guadalajara, Jalisco, Mexico, 44340 | |
GSK Investigational Site | |
Monterrey, Nuevo León, Mexico, 64020 | |
GSK Investigational Site | |
Mexico, D.F., Mexico, 06720 | |
GSK Investigational Site | |
Mexico, Mexico, 06700 | |
GSK Investigational Site | |
Mexico, Mexico | |
Netherlands | |
GSK Investigational Site | |
Den Haag, Netherlands, 2597 AX | |
GSK Investigational Site | |
Etten-leur, Netherlands, 4872 LA | |
GSK Investigational Site | |
Gouda, Netherlands, 2803 HH | |
GSK Investigational Site | |
Heerlen, Netherlands, 6416 EG | |
GSK Investigational Site | |
Nijmegen, Netherlands, 6525 GA | |
GSK Investigational Site | |
Zwolle, Netherlands, 8011 JW | |
New Zealand | |
GSK Investigational Site | |
Auckland, New Zealand, 1309 | |
GSK Investigational Site | |
Auckland, New Zealand, 1701 | |
GSK Investigational Site | |
Christchurch, New Zealand, 8001 | |
GSK Investigational Site | |
Lower Hutt, New Zealand, 6009 | |
GSK Investigational Site | |
Rotorua, New Zealand, 3201 | |
Norway | |
GSK Investigational Site | |
Harstad, Norway, 9480 | |
GSK Investigational Site | |
Levanger, Norway, 7600 | |
GSK Investigational Site | |
Lillehammer, Norway, 2609 | |
GSK Investigational Site | |
Skien, Norway, 3722 | |
GSK Investigational Site | |
Tønsberg, Norway, N-3117 | |
Peru | |
GSK Investigational Site | |
Callao, Peru, Callao 2 | |
GSK Investigational Site | |
Lima, Peru, Lima 27 | |
GSK Investigational Site | |
Lima, Peru, Lima 39 | |
Philippines | |
GSK Investigational Site | |
Manila, Philippines, 1000 | |
GSK Investigational Site | |
Manila, Philippines, 1003 | |
Poland | |
GSK Investigational Site | |
Grudziadz, Poland, 86-300 | |
GSK Investigational Site | |
Poznan, Poland, 61-544 | |
GSK Investigational Site | |
Warszawa, Poland, 02-341 | |
GSK Investigational Site | |
Wroclaw, Poland, 50-044 | |
GSK Investigational Site | |
Wroclaw, Poland, 50-088 | |
Puerto Rico | |
GSK Investigational Site | |
Caguas, Puerto Rico, 00726 | |
Romania | |
GSK Investigational Site | |
Brasov, Romania, 500366 | |
GSK Investigational Site | |
Bucharest, Romania, 11172 | |
GSK Investigational Site | |
Bucharest, Romania, 20983 | |
GSK Investigational Site | |
Bucharest, Romania | |
Russian Federation | |
GSK Investigational Site | |
Ekaterinburg, Russian Federation, 620102 | |
GSK Investigational Site | |
Moscow, Russian Federation, 115522 | |
GSK Investigational Site | |
Moscow, Russian Federation, 119049 | |
GSK Investigational Site | |
Moscow, Russian Federation, 129327 | |
GSK Investigational Site | |
Moscow, Russian Federation | |
GSK Investigational Site | |
Ryazan, Russian Federation, 390026 | |
GSK Investigational Site | |
Sankt-Petersburg, Russian Federation | |
GSK Investigational Site | |
Saratov, Russian Federation, 410053 | |
GSK Investigational Site | |
St. Petersburg, Russian Federation | |
GSK Investigational Site | |
Tula, Russian Federation, 300053 | |
GSK Investigational Site | |
Yaroslavl, Russian Federation, 150003 | |
GSK Investigational Site | |
Yaroslavl, Russian Federation, 150062 | |
South Africa | |
GSK Investigational Site | |
Korsten, Eastern Cape, South Africa, 6020 | |
GSK Investigational Site | |
Boksburg, Gauteng, South Africa | |
GSK Investigational Site | |
Muckleneuk, Gauteng, South Africa, 0001 | |
GSK Investigational Site | |
Parktown, Gauteng, South Africa, 2193 | |
GSK Investigational Site | |
Cape Town, South Africa, 7525 | |
GSK Investigational Site | |
Durban, South Africa, 4001 | |
GSK Investigational Site | |
Erasmus Kloof, Pretoria, South Africa, 0048 | |
GSK Investigational Site | |
Kempton Park, South Africa, 1619 | |
GSK Investigational Site | |
Observatory, South Africa, 7925 | |
GSK Investigational Site | |
Pinetown, South Africa, 7405 | |
Spain | |
GSK Investigational Site | |
Baracaldo/Vizcaya, Spain, 48903 | |
GSK Investigational Site | |
Barcelona, Spain, 08003 | |
GSK Investigational Site | |
Barcelona, Spain, 08025 | |
GSK Investigational Site | |
Barcelona, Spain, 08035 | |
GSK Investigational Site | |
Cordoba, Spain, 14004 | |
GSK Investigational Site | |
Granada, Spain, 18014 | |
GSK Investigational Site | |
Guadalajara, Spain, 19002 | |
GSK Investigational Site | |
La Coruña, Spain, 15006 | |
GSK Investigational Site | |
Mérida (Badajoz), Spain, 06800 | |
GSK Investigational Site | |
Oviedo, Spain, 33006 | |
GSK Investigational Site | |
Pamplona, Spain, 31008 | |
GSK Investigational Site | |
San Sebastián, Spain, 20014 | |
GSK Investigational Site | |
Santiago de Compostela, Spain, 15706 | |
GSK Investigational Site | |
Sevilla, Spain, 41071 | |
GSK Investigational Site | |
Valencia, Spain, 46017 | |
GSK Investigational Site | |
Villajoyosa, Spain, 3570 | |
Ukraine | |
GSK Investigational Site | |
Kharkiv, Ukraine, 61002 | |
GSK Investigational Site | |
Kharkiv, Ukraine, 61039 | |
GSK Investigational Site | |
Kiev, Ukraine | |
GSK Investigational Site | |
Kyiv, Ukraine, 03680 | |
GSK Investigational Site | |
Lviv, Ukraine, 79010 | |
United Kingdom | |
GSK Investigational Site | |
Truro, Cornwall, United Kingdom, TR1 3LJ | |
GSK Investigational Site | |
St Albans, Hertfordshire, United Kingdom, AL3 5PN | |
GSK Investigational Site | |
Manchester, Lancashire, United Kingdom, M13 9WL | |
GSK Investigational Site | |
Wirral, Merseyside, United Kingdom, CH49 9PE | |
GSK Investigational Site | |
Ashford, Middlesex, United Kingdom, TW15 3AA | |
GSK Investigational Site | |
Northampton, Northamptonshire, United Kingdom, NN1 5BD |
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00113308 |
Other Study ID Numbers: |
CXA30009 |
First Posted: | June 8, 2005 Key Record Dates |
Last Update Posted: | March 14, 2017 |
Last Verified: | March 2017 |
Keywords provided by GlaxoSmithKline:
Rheumatoid Arthritis COX-2 Inhibitor |
Additional relevant MeSH terms:
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases |
Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |